Neurizon Therapeutics Limited (ASX: NUZ)
Health Care · Pharmaceuticals · AU
AU$0.06
-3.23% today · -61.3% 1Y
Neurizon Therapeutics Limited (ASX: NUZ) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $33.34M and employs 36 people.
Over the last twelve months the share price has lost 61.3%, trading between 0.06 and 0.17.
Tweenvest scores Neurizon Therapeutics Limited across four factors: quality 42/100, value 40/100. Its strongest factor is quality.
NUZ price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $33.34M
- Revenue (TTM)
- $3.99M
- P/E
- —
- EPS
- -0.03
- Dividend yield
- —
- Beta (5Y)
- 1.32
- 52-week high
- AU$0.17
- 52-week low
- AU$0.06
- Avg volume (3M)
- —
- Shares outstanding
- 775.10M
- Employees
- 36
- Next earnings
- —
About Neurizon Therapeutics Limited
Neurizon Therapeutics Limited, a clinical stage biotechnology company, develops therapeutics for neurodegenerative diseases. The company develops drug discovery intellectual property for the treatment of neurological diseases. Its lead candidate is NUZ-001, a small molecule drug which is in Phase II clinical trials for the treatment of amyotrophic lateral sclerosis, as well as to treat other neurodegenerative diseases. The company was formerly known as PharmAust Limited and changed its name to Neurizon Therapeutics Limited in October 2024. Neurizon Therapeutics Limited was incorporated in 2000 and is based in Melbourne, Australia.
- ISIN
- AU0000357261
- Founded
- 2000
- Listed since
- Oct 4, 2001
- Exchange
- Australian Securities Exchange
- Currency
- AUD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.11T | $1,253.72 | +0.54% |
| Johnson & JohnsonNYSE: JNJ | $658.00B | $272.95 | -0.03% |
| Merck & Co., Inc.NYSE: MRK | $371.70B | $154.94 | +2.84% |
| Roche Holding AGSWX: ROP | $368.80B | CHF373.80 | +0.92% |
| Novartis AGSWX: NOVN | $300.52B | CHF126.76 | -0.52% |
| AstraZeneca PLCLSE: AZN | $256.25B | £124.76 | +3.02% |
| Novo Nordisk A/SCPSE: NOVO B | $206.64B | Dkr299.25 | -0.53% |
| Pfizer Inc.NYSE: PFE | $159.42B | $28.45 | +1.72% |
Figures last refreshed Aug 18, 2026.